TrialPharmacology research & perspectives2023

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.

Mohamad Shebley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.